United States
Symberix is an early-stage biotechnology startup with a vision to revolutionize pharmaceutical control of the microbiome. The company, founded in 2013 as a spin-out of the University of North Carolina at Chapel Hill, is focused on pioneering the development of symbiotic drugs that aim to improve human health by controlling bacteria without killing them.
At the core of Symberix's innovative approach is its scientific founder, Matthew Redinbo, PhD, who was the first to demonstrate the feasibility of therapeutically controlling the mammalian microbiome with small-molecule symbiotic drugs. Leveraging this breakthrough research, the company is advancing a first-in-class approach to improve the treatment of serious lower gastrointestinal (GI) diseases and mitigate the debilitating lower GI side effects associated with various cancer, pain, and immunosuppressive therapies.
Operating within the biotechnology and health care industries, Symberix is headquartered in the United States. The company's internal team, along with its scientific, clinical, and business advisors, possess a deep understanding of the microbiome and extensive experience in drug discovery, clinical development, and commercial biopharma.
As of now, there is no public information available regarding the last investment or the investors participating in it for Symberix.
With a compelling vision for safe and effective pharmaceutical control of the microbiome, Symberix stands at the forefront of potentially transformative advancements in the field of microbiome-targeted therapeutics.
